Clinical Gene Networks (CGN) is the first Swedish Bio-IT company currently situated at the Karolinska Science Park in Stockholm. The company was founded in 2003 by Johan Björkegren based on the idea that biological and pathological molecular events are best represented by gene regulatory networks (“GRNs”) that can be inferred directly from the clinical setting. In 2005, Vinnova (the Swedish Governmental Agency for Innovation Systems) awarded CGN for being one of the ten most promising Swedish start-ups all categories. During 2005 to 2011, CGN has been part of several integrated projects as a SME and Vinnova projects helping CGN to further finance and build the AtheroCode. CGN is not involved in a strategic collaboration with Novo Nordisk. In 2022, CGN signed a license agreement with Icahn school of Medicine at Mount Sinai in NY to commercialize the Beat-IT technology powered by Olink proteomics.

In collaboration with its commercial and academic partners, CGN has now identified 232 tissue and cross- tissue networks underlying carotid and coronary artery disease (CAD) (published in Nature Cardiovascular Disease 2022), the main causes of myocardial infarction (MI) and stroke.  With detailed network-maps acting to cause coronary artery disease (CAD), the goal is to provide pharmaceutical companies with better defined drug candidates (i.e. small molecular, chemical compounds and/or antibodies). In addition, we define sets of biomarkers in blood that can predict CAD before causing life- threatening clinical manifestations, like MI and stroke. CGN will also proposer from the concept that disease network status in any given individual will serve as the foundation on which personalized medicine eventually can evolve. Unlike isolated genes, the individual disease network status is the tool needed to tailor type and dosage of individual therapy regimes and to monitor the individual response to this regime over time.